Evaluation with COPD-PS questionnaire and Vitalograph COPD-6 portable device as a strategy for early diagnosis of COPD in primary care
DOI:
https://doi.org/10.17533/udea.iatreia.44Keywords:
forced expiratory volume, lung volume measurements, mass screening, pulmonary disease, chronic obstructive, risk factorsAbstract
Objective: To evaluate the use of the COPD-PS questionnaire and the Vitalograph COPD-6 portable device, as a strategy for the early diagnosis of chronic obstructive pulmonary disease (COPD) in two primary care units of the state social enterprise (ESE): Metrosalud, Medellin-Colombia in 2017.
Methods: A cross-sectional study to early detection of COPD, in people older than 35 years without previous diagnosis of the disease or other underlying respiratory diseases. The “COPD-PS” case detection-screening test was applied for identify respiratory risk factors and then the forced expiratory volume test (VEF1/VEF6) with the portable device Vitalograph-COPD-6.
Results: Of 1485 COPD-PS screening tests, 198 had a score equal to or greater than four, so they were tested with the Vitalograph device, of which 147 (74.2%) were positive.
Discussion: The underreporting of Chronic Obstructive Pulmonary Disease (COPD) is currently described as a serious problem worldwide. The use of the COPD-PS questionnaire for the identification of patients with risk factors and the Vitalograph COPD-6 as a lung function test, can be useful tools to implement an effective strategy to reduce COPD underreporting.
Downloads
References
(1) Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am. J. Respir. Crit. Care Med. 2013;187(4):382-6. DOI 10.1164/rccm.201209-1596OC.
(2.) Ayuso-Mateos JL, Nieto-Moreno M, Sánchez-Moreno J, Vázquez-Barquero JL. Clasificación Internacional del Funcionamiento, la Discapacidad y la Salud (CIF): aplicabilidad y utilidad en la práctica clínica. Med Clin. 2006;126(12):461-6.
(3) Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. The Lancet. 1997;349(9064):1498-504.
(4) López A, Shibuya K, Rao C, Mathers C, Hansell A, Held L, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397-412. DOI 10.1183/09031936.06.00025805.
(5) Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63(5):402-7. DOI 10.1136/thx.2007.085456.
(6) Menezes MB, Pérez-Padilla R, Jardim JB, Muiño A, López MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. The Lancet. 2005;366(9500):1875-81. DOI 10.1016/S0140-6736(05)67632-5.
(7) Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343-9. DOI 10.1378/chest.07-1361.
(8) Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. COPD screening efforts in primary care: what is the yield? Prim Care Respir J. 2007;16(1):41. DOI 10.3132/pcrj.2007.00009.
(9) Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. The Lancet. 2009;374(9691):721-32. DOI 10.1016/S0140-6736(09)61290-3.
(10) Montserrat-Capdevila J, Seminario MA, Godoy P, Marsal JR, Ortega M, Pujol J, et al. Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors. Medicina Clínica. 2018;151(10):383-9. DOI 10.1016/j.medcle.2018.09.006.
(11) López Varela MV, Rey A, Casas A, Ramirez A, Moreno D, Schiavi E, et al. Primary Care COPD Case Finding In Four Latin America Countries: The PUMA Study. AJS Journal. 2014;189:A2943.
(12) Casas Herrera A, Montes de Oca M, López Varela MV, Aguirre C, Schiav E, Jardim JR, et al. COPD underdiagnosis and misdiagnosis in a high-risk primary care population in four Latin American countries. A key to enhance disease diagnosis: The PUMA study. PLoS One. 2016;11(4):e0152266. DOI 10.1371/journal.pone.0152266.
(13) Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management
of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-91. DOI 10.7326/0003-4819-155-3-201108020-00008.
(14) Londoño D, García OM, Celis C, Giraldo M, Casas A, Torres C, et al. Guía de práctica clínica basada en la evidencia para la prevención, diagnóstico, tratamiento y seguimiento de la enfermedad pulmonar obstructiva crónica (EPOC) en población adulta. Acta med. colomb. 2014;39(2 SI):5-49.
(15) Benito CG, Río FG. ¿Qué podemos hacer ante la escasa implantación de la espirometría en atención primaria? Atención primaria. 2004;33(5):261-6. DOI 10.1016/S0212-6567(04)79412-3.
(16) De Miguel Díez J, Izquierdo LA, París JM, González-Moro JR, de Lucas Ramos P, Alonso-Vega GG. Fiabilidad del diagnóstico de la EPOC en atención primariay neumología en España. Factores predictivos. Arch. bronconeumol. 2003;39(5):203-8. DOI 10.1016/S0300-2896(03)75362-9.
(17) Thorn J, Tilling B, Lisspers K, Jörgensen L, Stenling A, Stratelis G. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis. Prim Care Respir J. 2012;21(2):159. DOI 10.4104/pcrj.2011.00104.
(18) Maranetra N, Chuaychoo B, Naruman C, Lertakyamanee J, Dejsomritrutai W, Chierakul N, et al. The cost-effectiveness of mini peak expiratory flow as a screening test for chronic obstructive pulmonary disease among the Bangkok elderly. J Med Assoc Thai. 2003;86(12):1133-9.
(19) Sierra VH, Mezquita MÁH, Cobos LP, Sánchez MG, Castellanos RD, Sánchez SJ, et al. Usefulness of the piko-6 portable device for early COPD detection in primary care. Arch Bronconeumol. 2018;54(9):460-6. DOI 10.1016/j.arbres.2018.04.015.
(20) Represas Represas C, Botana Rial M, Leiro Fernández V, González Silva AI, del Campo Pérez V, Fernández-Villar A. Validación del dispositivo portátil COPD-6 para la detección de patologías obstructivas de la vía aérea. Arch Bronconeumol. 2010;46(8):426-32. DOI 10.1016/j.arbres.2010.04.008.
(21) Jing J-y, Huang T-c, Cui W, Xu F, Shen H-h. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway
obstruction? A metaanalysis. Chest. 2009;135(4):991-8. DOI 10.1378/chest.08-0723.
(22) Kjeldgaard P, Lykkegaard J, Spillemose H, Ulrik CS. Multicenter study of the COPD-6 screening device: feasible for early detection of chronic obstructive pulmonary disease in primary care? Int J Chron Obstruct Pulmon Dis. 2017;12:2323-31. DOI 10.2147/COPD.S136244.
(23) Martinez FJ, Raczek AE, Seifer FD, Conoscenti CS, Curtice TG, D’Eletto T, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5(2):85-95. DOI 10.1080/15412550801940721.
(24) Bastidas A, Lemus M, Mayorga C, PierreB, Linares G, Melo A, PinzónN. Validación y reproducibilidad del puntaje COPD-PS para el diagnóstico de la EPOC. 11.º Congreso de la Asociación Latinoamericana de Tórax (ALAT). Arch Bronconeumol. 2018;54(Espec Cong 2):18-19.
(25) Quanjer P, Tammeling G, Cotes J, Pedersen O, Peslin R, Yernault J. Lung volumes and forced ventilatory flows. Work group on standardization of respiratory function tests. Eur Respir J. 1993;6 Suppl 16:5-40. DOI 10.1183/09041950.005s1693.
(26) Toda R, Hoshino T, Kawayama T, Imaoka H, Sakazaki Y, Tsuda T, et al. Validation of” lung age” measured by spirometry and handy electronic FEV1/FEV6 meter in pulmonary diseases. Intern Med. 2009;48(7):513-21. DOI 10.2169/internalmedicine.48.1781.
(27) Gonçalves JMF, Méndez LIP, Sáenz CG, Pérez DD, Manrique PV, García AJP. Impact of body mass index on the predictive capacity of the COPD-6 device in the detection of airflow obstruction. Med Clin (Barc). 2017;149(11):483-7. DOI 10.1016/j.medcli.2017.05.034.
(28) National Clinical Guideline Centre (UK). Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: Royal College of Physicians; 2010.
(29) Jones P, Harding G, Berry P, Wiklund I, Chen W, Leidy NK. Development and first validation of the COPD
Assessment Test. Eur Respir J. 2009;34(3):648-54. DOI 10.1183/09031936.00102509.
(30) Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44(4):873-84. DOI 10.1183/09031936.00025214.
(31) Cheng S-L, Lin C-H, Wang C-C, Chan M-C, Hsu J-Y, Hang L-W, et al. Comparison between COPD Assessment
Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients. J Formos Med Assoc. 2019;118(1):429-35. DOI 10.1016/j.jfma.2018.06.018.
(32) Pedrozo-Pupo J, Campo-Arias A. Desempeño clinimétrico de la escala de evaluación de la EPOC (CAT). Neumol Cir Torax. 2017;76(3):248-52.
(33) Camargo Rocha LAC, de Castro Pereira CA. Dyspnea in COPD: beyond the modified Medical Research Council. J. Bras. Pneumol. 2010;36(5):571-8. DOI 10.1590/S1806-37132010000500008.
(34) Santos SR, Lizzi ES, Vianna EO. Characteristics of undiagnosed COPD in a senior community center. Int J Chron Obstruct Pulmon Dis. 2014;9:1155-61. DOI 10.2147/COPD.S49521.
(35) Wadland WC, Zubek VB, Clerisme-Beaty EM, Ríos-Bedoya CF, Yawn BP. Patient Factors Influencing Respiratory-Related Clinician Actions in Chronic Obstructive Pulmonary Disease Screening. Am J Prev Med. 2017;52(1):94-9. DOI 10.1016/j.amepre.2016.07.015.
(36) Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015;148(4):971-85. DOI 10.1378/chest.14-2535.
(37) Jang S, Lee T, Cheong C, Lee Y, Choi N, Lee B. PMD72-cost-effectiveness analysis of adding spirometry to the national screening program for the purpose of copd case finding in South Korea. Value in Health. 2018;21:S255. DOI 10.1016/j.jval.2018.09.1521.
(38) Chuaychoo B, Maranetra N, Naruman C, Dejsomritrutai W, Lertakyamanee J, Chierkul N, et al. The most cost-effective screening method for chronic obstructive pulmonary disease among the Bangkok elderly. J Med Assoc Thai. 2003;86(12):1140-8.
(39) Vandevoorde J, Verbanck S, Gijssels L, Schuermans D, Devroey D, De Backer J, et al. Early detection of COPD: a case finding study in general practice. Respir Med. 2007;101(3):525-30. DOI 10.1016/j.rmed.2006.06.027.
(40) Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010 Apr;20;182(7):673-8. DOI 10.1503/cmaj.091784.
(41) Mapel DW, Dalal AA, Johnson P, Becker L, Hunter AG. A clinical study of COPD severity assessment by primary
care physicians and their patients compared with spirometry. Am J Med. 2015 Jun;128(6):629-37. DOI 10.1016/j.amjmed.2014.12.018.
(42) Varela López MV, Muiño A, Padilla RP, Jardim JR, Tálamo C, de Oca MM, et al. Tratamiento de la EPOC en 5 ciudades de América Latina: estudio PLATINO. Arch Bronconeumol. 2008 Feb;44(2):58-64. DOI 10.1016/s1579-2129(08)60016-6.
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
